COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

被引：0
|
作者：
Taxonera, C. [1 ]
de Andres-Nogales, F. [2 ]
Garcia, S. [3 ]
Sanchez-Guerrero, A. [4 ]
Menchen, B. [4 ]
Peral, C. [5 ]
Cabez, A. [5 ]
Gomez, S. [5 ]
Lopez, A. [6 ]
Casado, M. A. [2 ]
Menchen, L. [7 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] PORIB, Pozuelo De Alarcon M, Spain
[3] Hosp Univ Miguel Servet, Zaragoza, Spain
[4] Hosp Univ Puerta de Hierro Majadahonda, Madrid, Spain
[5] Pfizer SLU, Madrid, Spain
[6] Pfizer SLU, Madrid M, Spain
[7] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI17
引用
收藏
页码：S619 / S619
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN GERMANY
    Quon, P.
    Sardesai, A.
    Milev, S.
    DiBonaventura, M.
    Cappelleri, J. C.
    Kisser, A.
    Modesto, I
    Dietz, L.
    Dignass, A.
    Bargo, D.
    VALUE IN HEALTH, 2019, 22 : S617 - S617
  • [42] Biologics for the treatment of moderate-to-severe ulcerative colitis in pediatric patients
    Albenberg, Lindsey G.
    Mamula, Petar
    Kelsen, Judith R.
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 51 - 58
  • [43] Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update
    Burri, Emanuel
    Maillard, Michel H.
    Schoepfer, Alain M.
    Seibold, Frank
    Van Assche, Gert
    Riviere, Pauline
    Laharie, David
    Manz, Michael
    DIGESTION, 2020, 101 (SUPPL 1) : 2 - 15
  • [44] Cost-effectiveness analysis of amevivetm (Alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 330 - 330
  • [45] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4233 - 4245
  • [46] The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea
    Mar, J
    Rueda, JR
    Durán-Cantolla, J
    Schechter, C
    Chilcott, J
    EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (03) : 515 - 522
  • [47] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
    Ting Zhou
    Yanan Sheng
    Haijing Guan
    Advances in Therapy, 2021, 38 : 4233 - 4245
  • [48] Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment
    Wu, Jashin J.
    Rastogi, Shipra
    Menges, Brandy
    Lingohr-Smith, Melissa
    Lin, Jay
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB83 - AB83
  • [49] Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Hernandez, Luis
    Kuwabara, Hiroyo
    Shah, Anshul
    Yamabe, Kaoru
    Burnett, Heather
    Fahrbach, Kyle
    Koufopoulou, Maria
    Iwakiri, Ryuichi
    PHARMACOECONOMICS, 2020, 38 (01) : 69 - 84
  • [50] THE COST-EFFECTIVENESS OF ISOTRETINOIN IN PATIENTS WITH MODERATE-TO-SEVERE ACNE VULGARIS
    Shin, J.
    Hay, J.
    VALUE IN HEALTH, 2010, 13 (03) : A146 - A146
12345